171 related articles for article (PubMed ID: 28299581)
1. Expression of anoctamin 1 is associated with advanced tumor stage in patients with non-small cell lung cancer and predicts recurrence after surgery.
He Y; Li H; Chen Y; Li P; Gao L; Zheng Y; Sun Y; Chen J; Qian X
Clin Transl Oncol; 2017 Sep; 19(9):1091-1098. PubMed ID: 28299581
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.
Rusch V; Klimstra D; Venkatraman E; Pisters PW; Langenfeld J; Dmitrovsky E
Clin Cancer Res; 1997 Apr; 3(4):515-22. PubMed ID: 9815714
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer.
Cheng TL; Chang MY; Huang SY; Sheu CC; Kao EL; Cheng YJ; Chong IW
Chest; 2005 Sep; 128(3):1453-60. PubMed ID: 16162743
[TBL] [Abstract][Full Text] [Related]
4. ANO1 protein as a potential biomarker for esophageal cancer prognosis and precancerous lesion development prediction.
Shang L; Hao JJ; Zhao XK; He JZ; Shi ZZ; Liu HJ; Wu LF; Jiang YY; Shi F; Yang H; Zhang Y; Liu YZ; Zhang TT; Xu X; Cai Y; Jia XM; Li M; Zhan QM; Li EM; Wang LD; Wei WQ; Wang MR
Oncotarget; 2016 Apr; 7(17):24374-82. PubMed ID: 27016410
[TBL] [Abstract][Full Text] [Related]
5. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of overexpressed matrix metalloproteinase-2, mouse-double minute: 2 homolog and epidermal growth factor receptor in non-small cell lung cancer.
Jiang LY; Bi R; Ding FB; Wang MS; Mei J; He Y
J BUON; 2016; 21(2):341-8. PubMed ID: 27273943
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer.
Wang WP; Yan XL; Li WM; Ni YF; Zhao JB; Lu Q; Wang XJ; Sun Y; Chen P; Yan BY; Cui Y; Zhang ZP; Li XF
Pathol Res Pract; 2015 Dec; 211(12):939-47. PubMed ID: 26554593
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Calcium-Activated Chloride Channel ANO1/TMEM16A Suppresses Tumor Growth and Invasion in Human Lung Cancer.
Jia L; Liu W; Guan L; Lu M; Wang K
PLoS One; 2015; 10(8):e0136584. PubMed ID: 26305547
[TBL] [Abstract][Full Text] [Related]
9. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer.
Cao X; Chen YZ; Luo RZ; Zhang L; Zhang SL; Zeng J; Jiang YC; Han YJ; Wen ZS
Oncotarget; 2015 May; 6(13):11704-13. PubMed ID: 25868976
[TBL] [Abstract][Full Text] [Related]
11. Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease.
Mahmood MQ; Ward C; Muller HK; Sohal SS; Walters EH
Med Oncol; 2017 Mar; 34(3):45. PubMed ID: 28197929
[TBL] [Abstract][Full Text] [Related]
12. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
[TBL] [Abstract][Full Text] [Related]
13. HSP90B1 overexpression predicts poor prognosis in NSCLC patients.
Xu Y; Chen Z; Zhang G; Xi Y; Sun R; Wang X; Wang W; Chai F; Li X
Tumour Biol; 2016 Oct; 37(10):14321-14328. PubMed ID: 27599983
[TBL] [Abstract][Full Text] [Related]
14. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer.
Gately K; Forde L; Cuffe S; Cummins R; Kay EW; Feuerhake F; O'Byrne KJ
Clin Lung Cancer; 2014 Jan; 15(1):58-66. PubMed ID: 24210543
[TBL] [Abstract][Full Text] [Related]
15. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
[TBL] [Abstract][Full Text] [Related]
16. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer.
Richardson CM; Richardson D; Swinson DE; Swain WA; Cox G; O'Byrne KJ
Lung Cancer; 2005 Apr; 48(1):47-57. PubMed ID: 15777970
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of vascular invasion and standardization of its evaluation in stage I non-small cell lung cancer.
Hamanaka R; Yokose T; Sakuma Y; Tsuboi M; Ito H; Nakayama H; Yamada K; Masuda R; Iwazaki M
Diagn Pathol; 2015 Apr; 10():17. PubMed ID: 25884820
[TBL] [Abstract][Full Text] [Related]
19. Expression of flotillin-2 in human non-small cell lung cancer and its correlation with tumor progression and patient survival.
Wang YL; Yao WJ; Guo L; Xi HF; Li SY; Wang ZM
Int J Clin Exp Pathol; 2015; 8(1):601-7. PubMed ID: 25755751
[TBL] [Abstract][Full Text] [Related]
20. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
